Drug Profile
L 784520
Latest Information Update: 25 Oct 2018
Price :
$50
*
At a glance
- Originator Merck Frosst
- Class Anti-inflammatories
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 27 May 1998 New profile
- 27 May 1998 Discontinued-Preclinical for Inflammation in Canada (Unknown route)